Journey Medical Misses Annual Revenue Estimates, Shares Retreat After Full-Year Report
DERM is trading near its 52-week low of $5.51 (14% above the low).
Summary
Journey Medical reported full-year 2025 revenue of $61.9 million, falling short of Wall Street's $64.6 million estimate. This revenue miss, primarily attributed to declining sales of its acne treatment Accutane, led to a 7.7% decline in post-market trading. While the company's 8-K filing earlier today announced the results, this headline highlights the critical miss against expectations. For a small-cap pharmaceutical company, missing revenue estimates is a material event that can significantly impact investor sentiment and future outlook, despite overall revenue growth.
At the time of this announcement, DERM was trading at $6.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.1M. The 52-week trading range was $5.51 to $9.56. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.